Procalcitonin, soluble interleukin-2 receptor, and soluble E-selectin in predicting the severity of acute pancreatitis

被引:83
作者
Kylänpää-Bäck, ML
Takala, A
Kemppainen, EA
Puolakkainen, PA
Leppäniemi, AK
Karonen, SL
Orpana, A
Haapiainen, RK
Repo, H
机构
[1] Univ Helsinki, Cent Hosp, Dept Surg, Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Dept Anesthesia, Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland
[4] Univ Helsinki, Cent Hosp, Dept Clin Chem, Helsinki, Finland
[5] Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, Helsinki, Finland
关键词
procalcitonin; acute pancreatitis; severity; outcome measure; organ failure; soluble interleukin-2 receptor; soluble E-selectin; C-reactive protein;
D O I
10.1097/00003246-200101000-00016
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To investigate whether marker(s) of systemic inflammation detect, at an early stage of acute pancreatitis, patients who may ultimately develop severe disease. Design: Prospective study. Setting: University hospital emergency unit. Patients: Thirty patients with mild acute pancreatitis (SEV0 group) and 27 with severe acute pancreatitis. Of the latter, 11 did not develop organ failure (SEV1 group), whereas the other 16 patients developed acute respiratory failure and 9 of them also developed renal failure (SEV2 group). Interventions: Blood samples were collected at admission to the hospital (T-0), and at 12 hrs (T-12) and 24 hrs (T-24) after admission. Measurements and Main Results: The plasma concentrations of procalcitonin (PCT), soluble E-selectin (sE-selectin), soluble interleukin-2 receptor (sIL-2R), and the serum concentration of C-reactive protein (CRP) were monitored. PCT levels at T-0 were significantly higher in the SEV1 group (median 0.4 ng/mL, range 0.2-2.3) and the SEV2 group (0.8 ng/mL, 0.2-73.5) than in the SEV0 group (0.3 ng/mL, 0.1-3, p < .05 and p < .001, respectively). At T-12, PCT level in the SEV2 group was significantly higher than that in the SEV1 group (2.2 ng/mL, 0.2-86.6 vs. 0.4 ng/mL, 0.3-2.8, p = .05), as it also was at T-24 (2.2 ng/mL, 0.4-73.3 vs. 0.5 ng/mL, 0.3-4, p < .01). Among SEV2 patients, PCT concentration correlated negatively with the time elapsed between admission and the diagnosis of organ failure. At T-12, sIL-2R levels of the SEV1 group (1011 U/mL, range 334-2211) and the SEV2 group (1495 U/ml, range 514-4526) both differed significantly from the SEV0 group (636 U/ml, range 356-1678, p < .05 and p < .001, respectively) as they also did at T-24. Although CRP level in the SEV1 group at T-12 did not differ from the SEV0 group, the difference between SEV2 (272 <mu>g/mL, range 46-462) and SEV0 was significant (53 mug/mL, range 5-243, p < 0.01). sE-selectin levels did not differ between groups. Conclusions: At admission to hospital, concentrations of PCT, but not those of CRP, sE-selectin, or sIL-2R, are higher in patients with severe acute pancreatitis than in patients with mild pancreatitis. PCT test had sensitivity of 94% and specificity of 73% for development of organ failure. PCT may be useful to identify the patients who benefit from novel therapies aimed at modifying the course of systemic inflammation.
引用
收藏
页码:63 / 69
页数:7
相关论文
共 53 条
[1]   HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION [J].
ASSICOT, M ;
GENDREL, D ;
CARSIN, H ;
RAYMOND, J ;
GUILBAUD, J ;
BOHUON, C .
LANCET, 1993, 341 (8844) :515-518
[2]   Cytokines as predictors of severity in acute pancreatitis [J].
Balakrishnan, V ;
Philip, M .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1998, 13 (12) :1177-1179
[3]   BACTERIAL-CONTAMINATION OF PANCREATIC NECROSIS - A PROSPECTIVE CLINICAL-STUDY [J].
BEGER, HG ;
BITTNER, R ;
BLOCK, S ;
BUCHLER, M .
GASTROENTEROLOGY, 1986, 91 (02) :433-438
[4]   IDENTIFICATION OF AN INDUCIBLE ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE [J].
BEVILACQUA, MP ;
POBER, JS ;
MENDRICK, DL ;
COTRAN, RS ;
GIMBRONE, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (24) :9238-9242
[5]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[7]  
BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586
[8]   Pro- and anti-inflammatory cytokines during acute severe pancreatitis: An early and sustained response, although unpredictable of death [J].
Brivet, FG ;
Emilie, D ;
Galanaud, P .
CRITICAL CARE MEDICINE, 1999, 27 (04) :749-755
[9]  
BRUNKHORST FM, 1995, CHIR GASTROENTERO S2, V11, P42
[10]  
CARLOS TM, 1994, BLOOD, V84, P2068